← Product Code [NJD](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NJD) · K242307 # ACHIEVE Partial Knee System (K242307) _Ignite Orthomotion · NJD · Dec 16, 2024 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NJD/K242307 ## Device Facts - **Applicant:** Ignite Orthomotion - **Product Code:** [NJD](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NJD.md) - **Decision Date:** Dec 16, 2024 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3535 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use The ACHIEVE PARTIAL KNEE SYSTEM is intended for unicompartmental knee arthroplasty to treat one or more of the following conditions: - Moderately disabling joint disease of the knee resulting from painful osteo or post traumatic arthritis. - Revision of previous unsuccessful surgical procedures, including prior unicompartmental knee arthroplasty. - As an alternative to tibial osteotomy in patients with unicompartmental osteoarthritis. ## Device Story ACHIEVE Partial Knee System is a unicompartmental knee prosthesis for arthroplasty; treats painful osteoarthritis, post-traumatic arthritis, or failed prior surgeries. System comprises metal tibial tray (titanium alloy), polyethylene tibial insert (Cross-linked, Vitamin E UHMWPE), and metal femoral component (titanium alloy or cobalt-chromium). Components with engineered porous surfaces allow cementless or cemented fixation; non-porous components require cement. Used by orthopedic surgeons in clinical settings. Provides mechanical replacement of knee joint surfaces to restore function and reduce pain. Substantial equivalence established via non-clinical bench testing; no clinical data required. ## Clinical Evidence No clinical data. Substantial equivalence demonstrated through non-clinical bench testing, including range of motion (ASTM F2083), femoral fatigue (modified ASTM F3210), tibial tray fatigue (modified ASTM F3140), component interlock strength, wear resistance (ISO 14243-3), and contact stress testing. Porous structures validated per ASTM F1044, F1147, F1160, F1978, and F1854. ## Technological Characteristics Materials: Titanium alloy, cobalt-chromium, Cross-linked Vitamin E UHMWPE. Fixation: Cemented or cementless (porous-coated). Standards: ASTM F2083 (RoM), ASTM F3210/F3140 (fatigue), ISO 14243-3 (wear), ISO 10993-1 (biocompatibility), ISO 11607-1/2 (packaging), ISO 11137-1/2 (sterilization). Porous structure testing per ASTM F1044, F1147, F1160, F1978, F1854. Sterilization: VDmax method (SAL 10^-6). ## Regulatory Identification A knee joint femorotibial (uni-compartmental) metal/polymer porous-coated uncemented prosthesis is a device intended to be implanted to replace part of a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surface. It has no linkage across-the-joint. This generic type of device is designed to achieve biological fixation to bone without the use of bone cement. This identification includes fixed-bearing knee prostheses where the ultra-high molecular weight polyethylene tibial bearing is rigidly secured to the metal tibial baseplate. ## Special Controls *Classification.* Class II (special controls). The special control is FDA's guidance: “Class II Special Controls Guidance Document: Knee Joint Patellofemorotibial and Femorotibial Metal/Polymer Porous-Coated Uncemented Prostheses; Guidance for Industry and FDA.” See § 888.1 for the availability of this guidance. ## Predicate Devices - Restoris Porous Partial Knee System, MAKO Surgical Corp. ([K133811](/device/K133811.md)) ## Reference Devices - Uni Knee Resurfacing System, Overture Resurfacing Inc. ([K221292](/device/K221292.md)) - Persona Partial Knee System, Biomet, Inc. ([K161592](/device/K161592.md)) - Ignite Anatomic Shoulder System, Ignite Orthopedics LLC ([K202716](/device/K202716.md)) - MOTO Partial Knee System, Medacta International SA ([K162084](/device/K162084.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters 'FDA' in a blue square, followed by the words 'U.S. FOOD & DRUG ADMINISTRATION' in blue text. December 15, 2024 Ignite OrthoMotion Russell Parrott Chief Technology Officer 700 Park Avenue Suite F Winona Lake, Indiana 46590 Re: K242307 Trade/Device Name: ACHIEVE™ Partial Knee System Regulation Number: 21 CFR 888.3535 Regulation Name: Knee joint femorotibial (uni-compartmental) metal/polymer porous-coated uncemented prosthesis Regulatory Class: Class II Product Code: NJD, HSX Dated: November 15, 2024 Received: November 15, 2024 Dear Russell Parrott: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrb/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatory {2}------------------------------------------------ assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, # Lixin Liu -S Lixin Liu, Ph.D Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ # Indications for Use Submission Number (if known) K242307 Device Name ### ACHIEVE PARTIAL KNEE SYSTEM Indications for Use (Describe) The ACHIEVE PARTIAL KNEE SYSTEM is intended for unicompartmental knee arthroplasty to treat one or more of the following conditions: - · Moderately disabling joint disease of the knee resulting from painful osteo or post traumatic arthritis. - · Revision of previous unsuccessful surgical procedures, including prior unicompartmental knee arthroplasty. - · As an alternative to tibial osteotomy in patients with unicompartmental osteoarthritis. Fixation Methods Tibial trays and femoral components with engineered porous surfaces are intended for cemented or cementless use. Tibial trays and femoral components without engineered porous surfaces are intended for cemented use only. Type of Use (Select one or both, as applicable) × Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW! * The burden time for this collection of information is estimated to average 79 hours be response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {4}------------------------------------------------ Image /page/4/Picture/1 description: The image shows the logo for Ignite Orthomotion. The logo features a green flame-like graphic on the left side. To the right of the graphic is the word "IGNITE" in gray, with the word "ORTHOMOTION" in a smaller font size underneath. | 510(k) Summary | | |--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Prepared: | November 15, 2024 | | Submitter: | Ignite OrthoMotion, LLC
700 Park Ave.
Suite F
Winona Lake, IN 46590 | | Contact: | Russ Parrott
Chief Technology Officer
Phone: 574.527.2864
russ.parrott@igniteorthopedics.com | | Proprietary Name: | ACHIEVETM Partial Knee System | | Common Name: | Unicompartmental Knee Replacement System | | Classification: | Knee joint femorotibial (uni-compartmental) metal/polymer
porous coated uncemented prosthesis; (21 CFR §888.3535); Class II
Knee joint femorotibial metal/polymer non-constrained cemented
prosthesis; (21 CFR §888.3520); Class II | | Product Codes: | NJD, HSX | | Predicate Devices: | K133811 – Restoris Porous Partial Knee System, MAKO Surgical
Corp. | | Reference Devices: | K221292 – Uni Knee Resurfacing System, Overture Resurfacing Inc.
K161592 - Persona Partial Knee System, Biomet, Inc.
K202716 - Ignite Anatomic Shoulder System, Ignite Orthopedics LLC
K162084 – MOTO Partial Knee System, Medacta International SA | {5}------------------------------------------------ Image /page/5/Picture/1 description: The image shows the logo for Ignite Orthomotion. The logo features a green flame-like graphic on the left side. To the right of the graphic is the word "IGNITE" in a dark gray sans-serif font, and below that is the word "ORTHOMOTION" in a smaller, lighter gray font. # Device Description: The ACHIEVE™ PARTIAL KNEE SYSTEM is a knee joint femorotibial (unicompartmental) prosthesis that is intended for cementless or cemented fixation. The implant system consists of individually packaged implants: a metal tibial tray (titanium alloy), a polyethylene tibial insert, and a metal femoral component (titanium alloy or cobalt-chromium). All tibial inserts are composed of a Cross-linked, Vitamin E Ultra High Molecular Weight Polyethylene (Cross-Linked, VE UHMWPE). #### Indications for Use: The ACHIEVE PARTIAL KNEE SYSTEM is intended for unicompartmental knee arthroplasty to treat one or more of the following conditions: - . Moderately disabling joint disease of the knee resulting from painful osteo or post traumatic arthritis. - Revision of previous unsuccessful surgical procedures, including prior unicompartmental knee arthroplasty. - . As an alternative to tibial osteotomy in patients with unicompartmental osteoarthritis. #### Fixation Methods Tibial trays and femoral components with engineered porous surfaces are intended for cemented or cementless use. Tibial trays and femoral components without engineered porous surfaces are intended for cemented use only. #### Summary of Technologies/Substantial Equivalence: The implant and associated instruments within the ACHIEVE™ Partial Knee System are substantially equivalent to the predicate device in terms of its intended use and indications, material, design, sizes, and mechanical properties. Differences between the subject device system and the predicate device system do not raise different questions of safety and effectiveness. #### Non-Clinical Testing: The ACHIEVE™ Partial Knee System underwent non-clinical testing and analyses to support a determination of substantial equivalence to the predicate device. The following were completed: {6}------------------------------------------------ Image /page/6/Picture/1 description: The image shows the logo for Ignite Orthomotion. The logo features a green flame-like graphic on the left, followed by the word "IGNITE" in gray, all caps, and a sans-serif font. Below "IGNITE" is the word "ORTHOMOTION," also in gray, all caps, and a sans-serif font, but smaller than "IGNITE." # Predicate Comparison Evaluation A detailed comparison of key technologies and feature dimensions was made between the subject device and predicate devices. The comparison concluded the subject device key technologies and feature dimensions are substantially equivalent to that of the predicate devices. # Range of Motion (RoM) Evaluation An evaluation was conducted to ensure the RoM of the worst-case subject device components meet established specifications per ASTM F2083. The RoM targets were met. # Femoral Fatigue Testing Femoral fatigue testing was performed to 10 Mc per modified ASTM F3210. The acceptance criteria were met. #### Tibial Tray Fatigue Testing Tibial Tray fatigue testing was performed to 10 Mc per modified ASTM F3140. The acceptance criteria were met. #### Component Interlock Strength Testing To characterize the strength of attachment between the Tibial Tray and Tibial Bearing, static AP and ML shear testing and static tensile pull-off testing were performed. The acceptance criteria were met. #### Evaluation of Wear Resistance Wear testing was performed per ISO 14243-3. The wear rate of the subject device does not represent a new worst-case when compared directly to a predicate device. #### Tibial-Femoral Contact Area/Contact Stress Testing The contact surface areas and contact stresses were determined experimentally and an engineering justification demonstrated that the subject device does not represent a new worst-case for tibialfemoral contact area/contact stress when compared to the predicate devices. {7}------------------------------------------------ Image /page/7/Picture/1 description: The image shows the logo for Ignite Orthomotion. The logo features a green flame-like graphic on the left side, followed by the word "IGNITE" in gray, and the word "ORTHOMOTION" in a smaller font size below the word "IGNITE". The logo is simple and modern, and the use of green and gray gives it a clean and professional look. # Characterization of VE-UHMWPE The Vitamin E Ultra High Molecular Weight Polyethylene (Cross-linked, VE UHMWPE) material used for the Tibial Bearings of the ACHIEVE™ Partial Knee System was fully characterized per FDA Guidance, "Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices-Guidance for Industry and Food and Drug Administration Staff." #### Characterization of Titanium Articular Surface Coatings The wear properties of the Titanium Nitride (TiN) coating of the articular surface were characterized and found to be substantially equivalent to an uncoated cobalt-chrome alloy (CoCrMo) when articulating with a UHMWPE bearing couple. An engineering justification demonstrated that the subject device does not represent a new worst-case for wear resistance, abrasion-resistance and surface hardness of the articulating surfaces when compared to the predicate device, which is made from CoCrMo. #### Biocompatibility Assessments The contact classification for the subject devices is Implant, Bone/Tissue with permanent contact (>30 days). A Biocompatibility Assessment was completed and provided per ISO 10993-1 and FDA Guidance Document Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process. The devices were found to be biocompatible. #### Porous Structure Characterization The porous structure used for the subject device was evaluated per ASTM F1044 (Static Shear Strength), ASTM F1147 (Static Tensile Strength), ASTM F1160 (Shear Fatigue), ASTM F1978 (Abrasion Resistance), and ASTM F1854 (Stereological Evaluation). The engineered porous structure meets the recommendations of the Class II Special Controls Guidance Document: Knee Joint Patellfemorotibial and Femorotibial Metal/Polymer Porous-Coated Uncemented Prostheses; Guidance for Industry and FDA. #### Shelf-Life Evaluation A shelf-life evaluation per ISO 11607-1 and ISO 11607-2 was completed on the packaging materials that make up the sterile barrier. A five-year shelf life was established based on the resultant data. {8}------------------------------------------------ Image /page/8/Picture/1 description: The image shows the logo for Ignite Orthomotion. The logo features a green flame-like graphic on the left, followed by the word "IGNITE" in gray, uppercase letters. Below "IGNITE" is the word "ORTHOMOTION" in smaller, gray, uppercase letters. The logo is clean and modern, with a focus on the company name and a visual element that suggests energy or movement. # Sterilization Validation Sterilization validation was completed using the VDmax method specified in ISO 11137-1 and ISO 11137-2. The Sterility Assurance Level (SAL) was found to be 10-6. ### Clinical Testing: Clinical testing was not necessary to demonstrate substantial equivalence of the ACHIEVE™ Partial Knee System to the predicate devices. #### Conclusion: A comparison of the subject and predicate devices, including comparison of the intended use, technological characteristics, and non-clinical testing results has demonstrated that the subject device has a safety and effectiveness profile equivalent to that of the predicate device. Thus, the subject device is substantially equivalent to the predicate device. --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NJD/K242307](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/NJD/K242307) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com